Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Fish and Richardson
Julphar
Deloitte
McKinsey
Medtronic
Cantor Fitzgerald
UBS
Covington

Generated: December 11, 2018

DrugPatentWatch Database Preview

CRIXIVAN Drug Profile

« Back to Dashboard

When do Crixivan patents expire, and what generic alternatives are available?

Crixivan is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this drug.

This drug has forty-two patent family members in thirty-five countries.

The generic ingredient in CRIXIVAN is indinavir sulfate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the indinavir sulfate profile page.

Drug patent expirations by year for CRIXIVAN
Generic Entry Opportunity Date for CRIXIVAN
Generic Entry Date for CRIXIVAN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for CRIXIVAN
Medical Subject Heading (MeSH) Categories for CRIXIVAN
Synonyms for CRIXIVAN
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxyindan-1-yl]amino]-5-oxo-pentyl]-N-tert-butyl-4-(3-pyridylmethyl)piperazine-2-carboxamide
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
(S)-1-((2S,4R)-4-benzyl-2-hydroxy-5-(((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino)-5-oxopentyl)-N-(tert-butyl)-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
2-benzyl-5-[(2S)-2-(tert-butylcarbamoyl)-4-(pyridin-3-ylmethyl)piperazin-1-yl]-2,3,5-trideoxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-D-erythro-pentonamide
216884-06-9
2avo
2avs
2avv
2bpx
378I179
90708-EP2272516A2
90708-EP2298783A1
90708-EP2305640A2
90708-EP2305680A2
9MG78X43ZT
AB00698241-07
AC-20034
AC1L1U7I
AK115103
AKOS000280989
AM84463
BDBM50067593
BIDD:GT0378
BIDD:PXR0141
C-23355
C07051
C36H47N5O4
CC-29506
CHEBI:44032
CHEMBL115
Compound J
Crixivan (TM)
CS-2930
CTK8E9721
D-erythro-Pentonamide, 2,3,5-trideoxy-N-((1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-((2S)-2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-
D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, (1(1S,2R),5(S))-
D-erythro-Pentonamide,2,3,5-trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-
DB00224
DR003379
DTXSID4043802
HE313403
HE313404
HY-B0689
IDV
indinavir
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN:INN:BAN]
Indinavir [USAN]
Indinavir & IFNL1
Indinavir & IFNL2
Indinavir & IFNL3
Indinavir & IL-28A
Indinavir & IL-28B
Indinavir & IL-29
Indinavir & Interferon lambda-1
Indinavir & Interferon lambda-2
Indinavir & Interferon lambda-3
Indinavir & Interleukin 28A
Indinavir & Interleukin 28B
Indinavir & Interleukin 29
Indinavir anhydrous
Indinavir, Sulfate (1:1)
J-008694
KB-296154
L-735 524
L-735,524
L-735524
L735,524
LS-173382
MK-639
MK1
MK639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-03
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
RT-013332
SC-26523
SCHEMBL6317
UNII-9MG78X43ZT
ZINC22448696

US Patents and Regulatory Information for CRIXIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for CRIXIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-005 Dec 17, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-005 Dec 17, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Premature patent expiration for: CRIXIVAN

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
➤ Try a Free Trial CRIXIVAN ➤ Try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Chinese Patent Office
Boehringer Ingelheim
Fish and Richardson
Federal Trade Commission
Fuji
AstraZeneca
US Department of Justice
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.